https://www.selleckchem.com/pr....oducts/bms303141.htm
Following addition of a biosimilar filgrastim product to the formulary, sites in the authors' provincial health authority transitioned from using the originator filgrastim to the biosimilar for autologous stem cell mobilization. To assess the effect on patient outcomes of a universal change to use of the biosimilar filgrastim in stem cell mobilization. This retrospective pre-post study included patients undergoing autologous stem cell mobilization at 2 cancer hospitals in Alberta, Canada, between July 1, 2018, and November 30, 2019. C
Like
Comment
Share
